UPDATED 8:45 AM PT — Monday, May 18, 2020
U.S. biotech firm Moderna has reported some success in an early clinical trials for a potential coronavirus vaccine.
On Monday, the company announced the potential vaccine produced COVID-19 antibodies in all 45 participants in a phase one trial so far. Participants have reportedly developed antibody levels similar to those who have recovered from the virus.
Moderna said it hasn’t noted any serious side effects. The firm’s CEO Stephane Bancel said phase one is still ongoing and previewed the next steps of the trial.
— Moderna (@moderna_tx) May 18, 2020
If phase two and three trials go well, the potential vaccine could be available for widespread use by the end of the year or early 2021.